The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Gemtuzumab-based induction regimens produce higher rates of MRD negativity in CBF-AML
Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, discusses the study describing overall responses after standard inductions with high dose daunorubicin (90mg/m2) vs standard dose daunorubicin (60mg/m2) with gemtuzumab ozogamicin (GO) in favorable risk acute myeloid leukemia (AML). Incorporation of GO to 7+3 with standard dose daunorubicin resulted in comparable remission rates to 7+3 with high dose daunorubicin. Importantly, GO-based regimens produce higher rates of MRD negativity compared to 7+3 with high dose daunorubicin in CBF AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
